



Thursday, 17 December 2009

## PHARMACEUTICAL JOURNAL PUBLICATION

---

OBJ Ltd (ASX: OBJ) notes the overnight publication by the Journal of Pharmaceutical Science of a paper into the enhanced transdermal delivery of Naltrexone by the Company's technology.

The paper is published by Wiley Interscience and the American Pharmacists Association and is available on the webpage [interscience.wiley.com/journal/123213574/abstract](http://interscience.wiley.com/journal/123213574/abstract).

- Ends -

### For more information:

Mr Glyn Denison          Director

P +618 9443 3011

E [info@obj.com.au](mailto:info@obj.com.au)

W [www.obj.com.au](http://www.obj.com.au)

### About OBJ:

OBJ is an early-stage drug delivery Company focused on the development of transdermal drug delivery technology for use in the pharmaceutical and cosmetic industries. The Company is developing two drug delivery technologies for the transdermal delivery of pharmaceutical and cosmetic compounds through or into the skin without the need for injections. The foundation technology, Dermaportation (DP), is a powered drug delivery technology that uses battery power to generate time-varying electromagnetic fields. The Company's second technology, Enhanced Transdermal Polymer (ETP) is an unpowered drug delivery technology that uses a magnetic gradient technique to enhance transdermal delivery. The DP platform is designed to be integrated into a battery-operated transdermal patch for pharmaceutical applications, whereas the ETP platform is intended as a powerless patch targeted at the competitive over-the-counter pharmaceutical and cosmetic markets.